Steven E. Hyman

Steven E Hyman is Harvard University Distinguished Service Professor and Harald McPike Professor of Stem Cell and Regenerative Biology. He is also a Core Institute Member of the Broad Institute of MIT and Harvard and Director of the Broad Program in Brain Health supporting basic and translational research and technology development for psychiatric, neurodevelopmental, and neurodegenerative disorders. Hyman is principal investigator of the Psychiatric Biomarkers Network, a multi-institutional and multi-sector collaboration focused on fluid biomarkers for schizophrenia spectrum and bipolar disorders. From 2012-2024 Hyman directed the Stanley Center for Psychiatric Research at Broad, from 2001 to 2011 he served as Provost (chief academic officer) of Harvard University, and from 1996 to 2001 he was Director of the US National Institute of Mental Health (NIMH). At NIMH he modernized its research investments, focusing on on neuroscience, emerging genomic technologies, and initiating a series of large pragmatic clinical trials to inform practice. He has served as Editor of the Annual Review of Neuroscience (2002-2016) and Chair of the International Advisory Committee on the revision of the Mental, Behavioral, or Neurodevelopmental Disorders section for ICD-11 for the World Health Organization (2006-2014). He was founding President of the International Neuroethics Society (2008-2013), President of the Society for Neuroscience (2015), and President of the American College of Neuropsychopharmacology (2018). He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, a distinguished life fellow of the American Psychiatric Association, and a member of the National Academy of Medicine (NAM) where he chaired the Forum on Neuroscience and Nervous System Disorders (2012-2018), served on the Council (2012-2018), and represented NAM on the governing board of the National Research Council, the operating arm of the National Academies of Sciences, Engineering, and Medicine (2016-2019). He currently chairs the Boards of Directors of the Charles A. Dana Foundation (NY) and the Wyss Center for Bio and Neuroengineering (Geneva, Switzerland). In the private sector he is a Director of Voyager Therapeutics, Cyclerion Therapeutics, and Vesalius Therapeutics. He serves on the Scientific Advisory Boards of J&J Innovative Medicines and F-Prime Capital. He received his BA, summa cum laude, from Yale, an MA from the University of Cambridge, which he attended as a Mellon fellow studying History and Philosophy of Science, and an MD, cum laude, from Harvard Medical School.